Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
The NGDx group is looking for an experienced program manager to establish and oversee NGDx’s portfolio of clinical trial analysis projects. This hire will interface between the NGDx laboratory, NGDx bioinformatics, and collaborating clinical project teams to identify new projects, establish project strategy, set priorities, monitor progress, and communicate results. The successful candidate will work with multi-disciplinary teams and support the discovery and validation of biomarkers in oncology trials.
Provide strategic leadership for the NGDx clinical project portfolio
Ensure effective communication and alignment between NGDx and collaborating clinical project teams
Contribute to the development of project strategy and experimental design
Integrate cross functional laboratory and analytic activities into project plan according to project objectives and timelines
Organize and conduct project team meetings
Track progress, adherence to strategy and plan, and identify bottlenecks
Work with project leaders and lab team to ensure completion of project documentation and reporting requirements
Proactively identify and manage issues and development of counter-measures and contingency plans
Engage clinical project teams to identify new project opportunities
Foster high performing team and meeting effectiveness
Provide strategic scientific input both internally and to project teams
Network internally and externally with scientists on project activities
Candidates must have PhD or equivalent and 5+ years in pharmaceutical R&D with project management skills and experience in cross-functional setting
Expert planning and tracking skills, capable of managing multiple projects with ease, well–organized, excellent time management with respect to priorities and self-management
Knowledge of drug discovery and development processes and good understanding of basic science. Experience with cancer genetics and/or Next Generation Sequencing approaches preferred.
Strong analytical skills for integrating and interpreting interdisciplinary project information
Creative problem solving skills for maintaining project timelines and developing alternative scenarios
Expert team player with demonstrated ability to build collaborative relationships and positively influence team members in a cross-cultural environment
Excellent communication skills (written and oral)
Excellent presentation skills
Strong management and leadership skills, with a proven ability to lead cross-functional teams effectively in a dynamic environment
The ideal candidate will be collaborative, innovative, and self-directed
Qualified candidates can learn more and apply here:
About Novartis Institute for Biomedical Research:
The Novartis Institutes for BioMedical Research is the global pharmaceutical research organization for Novartis. The NIBR research network is comprised of more than 6,000 scientists, physicians, and business professionals working together across 10 locations around the world to discover innovative medicines that treat diseases with high unmet medical need. Novartis employs more than 2,000 associates in Cambridge, making it the city’s largest private employer and ideally situated in one of the leading life science communities in the world.
NIBR conducts research globally with sites in Emeryville, California; Cambridge, MA; East Hanover, NJ; Basel, Switzerland; Horsham, UK; and Shanghai, China.
About the Next Generation Sequencing Group
The ability to sequence each patient’s genome in great detail, quickly and inexpensively, is changing the practice of medicine. At NIBR, we are dedicated to the development of therapies that improve clinical outcomes for patients. Next generation sequencing and other cutting-edge molecular characterization technologies will be important tools for discovering breakthrough therapeutics, and for delivering the right medicines to the right patients.
The NGDx team leverages cutting-edge technologies such as next generation sequencing for characterizing human tissues, by individual lesions and by pathway signatures relevant to therapeutic response. The goal is to develop a robust and comprehensive molecular profile for each patient. To this end, the group will begin by developing capabilities to characterize therapeutically relevant genetic lesions and pathway signatures in human cancer.